

**Supplementary Table S3** Univariate analysis for patients with GC

Parameters	DFS		OS	
	HR (95%CI)	P value	HR (95%CI)	P value
<b>Age</b>				
≥60 VS. < 60	0.89(0.45-1.75)	0.730	1.10(0.52-2.35)	0.806
<b>Tumor location</b>		0.186		0.441
Gastric body VS.EGJ/Cardia	0.23(0.03-1.80)	0.161	0.44(0.06-3.38)	0.428
Gastric antrum VS.EGJ/Cardia	0.37(0.05-1.83)	0.339	0.66(0.09-4.94)	0.688
<b>Histological type</b>		0.015		0.053
Undifferentiated	VS.	4.87(1.67-14.22)	4.40(1.30-14.83)	0.017
Differentiated				
Mixed VS. Differentiated	1.11(0.50-2.43)	0.803	1.40(0.63-3.11)	0.415
<b>Lauren type</b>		0.367		0.417
Diffuse VS. Intestinal	1.45(0.75-2.82)	0.270	1.33(0.64-2.74)	0.443
Mixed VS. Intestinal	0.73(0.25-2.14)	0.569	0.58(0.17-1.95)	0.376
<b>p-TNM stage</b>				
III VS. II	2.30(0.82-6.48)	0.114	2.58(0.79-8.44)	0.117
<b>HER2</b>				
Positive VS. Negative	0.94(0.40-2.25)	0.897	0.89(0.35-2.30)	0.814
<b>PD-L1</b>				
Positive VS. Negative	0.51(0.27-0.95)	0.035	0.44(0.22-0.86)	0.016
<b>TMB</b>				
TMB-H VS. TMB-L	0.98(0.50-1.89)	0.941	0.84(0.40-1.75)	0.646
<b>Microsatellite status</b>				
MSI-H VS. MSS	0.63(0.19-2.03)	0.434	0.42(0.10-1.76)	0.235
<b>CD4/CD8</b>				
High VS. Low	0.28(0.14-0.57)	0.000	0.22(0.10-0.51)	0.000
<b>CD86/CD163</b>				
High VS. Low	1.11(0.60-2.07)	0.735	1.19(0.61-2.31)	0.609
<b>LRP1B on TCs</b>				
Positive VS. Negative	0.22(0.05-0.89)	0.034	0.25(0.06-0.99)	0.049
<b>LRP1B on ICs</b>				
Positive VS. Negative	0.91(0.65-1.28)	0.580	1.98(0.69-1.41)	0.925

GC, gastric cancer; DFS, disease free survival; OS, overall survival; HR, hazard ratio; CI, confident intervention; EGJ, gastroesophageal junction; p, pathological; HER-2; human epidermal growth factor receptor 2; PD-L1, programmed cell death ligand 1; TMB, tumor mutation burden; MSS, microsatellite stability; MSI, microsatellite instability.